Case report: Long-term response to a combination of immune checkpoint inhibitors as a single treatment for multiple synchronous cancers: a case study.

Date publication

décembre 2024

Journal

Frontiers in immunology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BENDER Laura

Tous les auteurs :
Ghammem N, Bischoff H, Chiappa P, Somme L, Moinard-Butot F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39737185

Résumé

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by enhancing the antitumor immune response. This case describes an 80-year-old male with synchronous multiple primary malignancies (MPMs), including lung metastatic hepatocellular carcinoma (HCC), and non-small cell lung carcinoma (NSCLC), and brain metastatic urothelial carcinoma, who was treated with dual ICI therapy.

Mots clés

hepatocellular carcinoma, immune checkpoint inhibitor, lung cancer, multiple primary malignancies, urothelial carcinoma

Référence

Front Immunol. 2024 12 16;15:1487227